Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Libtayo coverage & Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0398

    Libtayo (cemiplimab-rwlc) — coverage and prior authorization

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0398 alerts

    Get alerted when Policy IC-0398 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Viva Health medical policy coverage, dosing limits, and prior authorization requirements for intravenous cemiplimab-rwlc (Libtayo) across multiple oncology indications for adult members.

    Policy Summary
    PayerViva Health
    PolicyLibtayo (cemiplimab-rwlc) — coverage and prior authorization
    Policy CodePolicy IC-0398
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial approval valid for 180 days; renewable every 180 days when criteria are met).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial prior authorization validity
    700 mgmax dose cSCC
    350 mgmax dose other indications
    18+minimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    35 doses
    max renewal cSCC/BCC
    J9119HCPCS code

    Coverage and Medical Necessity Criteria

    Universal Criteria

    Covered when ALL of the following are met

    Age: Member is at least 18 years of age
    Prior PD-1/PD-L1 therapy: Member has not received previous PD-1/PD-L1-directed therapy unless otherwise specified

    Prior PD-1/PD-L1 therapy may be allowed where an indication-specific exception is specified in the policy.

    Anal Carcinoma

    Covered when ALL of the following are met

    Histology: Member has squamous cell carcinoma
    Use setting: Used as a single agent as subsequent therapy for metastatic disease OR used in combination with paclitaxel and carboplatin then continued as single agent
    Disease setting: Used for treatment of inguinal node recurrence OR used as first-line treatment for metastatic disease

    Cutaneous Squamous Cell Carcinoma (cSCC)

    Covered when ALL of the following are met

    Agent use: Used as a single agent
    Indication groups: Member has metastatic, locally advanced, or recurrent disease OR unresectable or incompletely resected satellitosis/in-transit metastasis (and is not a candidate for curative surgery or radiation) OR used as adjuvant therapy for high risk of recurrence after surgery and radiation OR used as neoadjuvant therapy for regional or satellitosis/in-transit metastatic disease OR member has very high-risk disease

    Very high-risk features and detailed nodal/non-nodal risk features are specified in policy (e.g., preoperative tumor diameter >4 cm, poor differentiation, invasion beyond subcutaneous fat, perineural invasion, lymphovascular involvement, etc.).

    Cervical Cancer

    Covered when ALL of the following are met

    Used as a single agent as subsequent therapy

    Member has recurrent or metastatic disease.

    Basal Cell Carcinoma (BCC)

    Covered when ALL of the following are met

    Used as a single agent

    Member has locally advanced or metastatic disease OR has nodal disease and surgery is not feasible.

    Non-Small Cell Lung Cancer (NSCLC)

    Covered when criteria for one of the following branches are met

    Advanced/metastatic disease: Member has recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease without evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation
    Combination with platinum-based chemo branch: Used in combination with platinum-based chemotherapy (e.g., paclitaxel + carboplatin or pemetrexed + carboplatin/cisplatin) and used as first-line therapy for tumors negative for actionable biomarkers OR for tumors positive for select biomarkers (EGFR exon 20 insertion, BRAF V600E, NTRK fusions, MET exon 14 skipping, NRG1 fusion, ERBB2) OR used as subsequent therapy for members positive for specified biomarkers after targeted therapy

    Actionable biomarkers and examples of regimens are specified in policy; KRAS G12C also noted as an allowed biomarker context.

    Monotherapy high PD-L1 branch: Used as single agent when tumors are negative for actionable biomarkers and have PD-L1 Tumor Proportion Score (TPS) ≥ 50% as determined by an FDA-approved or CLIA-compliant test — can be first-line or continuation maintenancePD-L1 TPS ≥ 50%

    MSI-H/dMMR or POLE/POLD1 Ultra-Hypermutated Tumors (Small Bowel, Colon, Appendix, Rectum)

    Covered when ALL of the following are met

    Agent use: Used as single agent treatment
    Biomarker requirement: Member has MSI-H/dMMR disease OR POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., tumor mutational burden > 50 mutations/megabase) as determined by an FDA-approved or CLIA-compliant test

    Applies to small bowel, colon, appendiceal, and rectal cancers as specified.

    Disease extent: Used for advanced/metastatic disease OR locally unresectable or medically inoperable disease OR recurrent/progressive/metastatic peritoneal/extraperitoneal disease depending on tumor site

    Site-specific uses (small bowel, colon, appendix, rectum) are provided in policy.

    Vaginal and Vulvar Cancer

    Covered when ALL of the following are met

    Used as a single agent as subsequent therapy

    For vaginal cancer: member has recurrent or metastatic disease. For vulvar cancer: member has advanced or recurrent/metastatic disease.

    Appendiceal Neoplasms and Cancers (Compendia Recommended)

    Covered when ALL of the following are met

    Agent use: Used as single agent treatment

    Compendia-recommended indication.

    Biomarker requirement: Member has MSI-H/dMMR disease OR POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB > 50 mut/Mb) as determined by an FDA-approved or CLIA-compliant testTMB > 50 mut/Mb (example)

    Compendia recommended indication

    Disease extent: Used for recurrent, progressive, metastatic peritoneal-only, or extraperitoneal disease

    Rectal Cancer (Compendia Recommended)

    Covered when ALL of the following are met

    Agent use: Used as single agent treatment

    Compendia-recommended indication.

    Biomarker requirement: Member has MSI-H/dMMR disease OR POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB > 50 mut/Mb) as determined by an FDA-approved or CLIA-compliant testTMB > 50 mut/Mb (example)

    If confirmed using an FDA-approved assay, see companion diagnostics guidance.

    Disease extent: Used for locally unresectable, medically inoperable, advanced, or metastatic disease

    Diagnosis-based coverage

    Covered when the patient's diagnosis matches one of the ICD-10 codes listed in Appendix 1

    Diagnosis match: Patient has one of the ICD-10 codes listed in Appendix 1 supporting use of Libtayo

    Submit the applicable ICD-10 code from Appendix 1 with requests; clinical criteria and other coverage rules are in other sections of the policy.

    For neoadjuvant therapy for cutaneous squamous cell carcinoma (cSCC), the policy specifies that the initial prior authorization is time‑limited and may not be renewed. Authorization for neoadjuvant cSCC is therefore limited to the initial approval period defined at the time of request and cannot be extended under the renewal rules.

    The dosing and administration section includes explicit maximum duration limits for specific indications that effectively cap total therapy exposure. Examples in the policy include: metastatic/locally advanced/recurrent cSCC — up to 24 months, adjuvant cSCC — up to 48 weeks, neoadjuvant cSCC — up to 4 doses, and cervical/vaginal/vulvar cancers — up to 96 weeks. These limits functionally restrict how long cemiplimab may be provided even when initial authorization and renewal criteria are otherwise met.

    This extract does not list Medicare Part B covered diagnosis codes. Where applicable, providers must follow any relevant CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), or Local Coverage Articles (LCAs) for Medicare Part B coverage; the policy refers providers to CMS resources for those determinations.

    Continued therapy and renewal are contingent on clinical benefit and safety. Renewal may be denied if the member does not demonstrate disease response or stabilization as defined by the policy (no tumor decrease or stabilization) or if there is unacceptable toxicity (for example severe infusion reactions or severe immune‑mediated adverse events). These are operational triggers for denying continuation of therapy.

    Initial Authorization and Dosing Requirements

    Initial therapy requirements

    Initial approval criteria

    Age and prior PD-1/PD-L1 therapy: Member is ≥18 years AND has not received previous PD-1/PD-L1-directed therapy unless otherwise specified

    Prior authorization validity is provided initially for 180 days.

    Initial dosing and administration

    Dosing guidance per indication

    Metastatic/locally advanced/recurrent cSCC: Administer 350 mg IV every 3 weeks for up to 24 months in members without progression or unacceptable toxicitymax 24 months
    Adjuvant cSCC:

    Renewal, Continuation and Treatment Limits

    Continuation and renewal limits

    Renewal/continuation rules and limits vary by indication

    Adjuvant cSCC renewal limit: Adjuvant therapy for cSCC may be renewed up to a maximum of 48 weeks of therapymax 48 weeks
    Metastatic/locally advanced cSCC and BCC renewal limit: Renewable up to a maximum of 24 months of therapy (35 doses)35 doses / 24 months
    Cervical/vaginal/vulvar renewal limit: Cervical, vaginal, and vulvar cancers may be renewed up to a maximum of 96 weeks of therapy (32 doses)32 doses / 96 weeks

    Billing Codes, Diagnosis Codes and Dosing Units

    Dosing HCPCS unitsHCPCSCovered
    HCPCS unit: 700 mgMax units per dose for cSCC (700 billable units every 42 days)
    HCPCS unit: 350 mgMax units per dose for all other indications (350 billable units every 21 days)
    Covered HCPCS CodesHCPCSCovered
    J9119Injection, cemiplimab-rwlc, 1 mg; 1 billable unit = 1 mg
    NDCNDCCovered
    61755-0008-xxLibtayo 350 mg/7 mL single-dose vial
    Covered ICD-10 Diagnosis Codes (partial list shown in document)ICD-10Covered
    C17.0Malignant neoplasm of duodenum
    C17.1Malignant neoplasm of jejunum
    C17.2Malignant neoplasm of ileum
    C17.3Meckel's diverticulum, malignant
    C17.8Malignant neoplasm of overlapping sites of small intestine
    C17.9Malignant neoplasm of small intestine, unspecified
    C18.0Malignant neoplasm of cecum
    C18.1Malignant neoplasm of appendix
    C18.2Malignant neoplasm of ascending colon
    C18.3Malignant neoplasm of hepatic flexure
    1–10 of 41
    1/5
    Covered ICD-10 Diagnosis CodesICD-10Covered
    C34.82Malignant neoplasm of overlapping sites of left bronchus and lung.
    C34.90Malignant neoplasm of unspecified part of unspecified bronchus or lung.
    C34.91Malignant neoplasm of unspecified part of right bronchus or lung.
    C34.92Malignant neoplasm of unspecified part of left bronchus or lung.
    C44.01Basal cell carcinoma of skin of lip.
    C44.02Squamous cell carcinoma of skin of lip.
    C44.111Basal cell carcinoma of skin of unspecified eyelid, including canthus.
    C44.1121Basal cell carcinoma of skin of right upper eyelid, including canthus.
    C44.1122Basal cell carcinoma of skin of right lower eyelid, including canthus.
    C44.1191Basal cell carcinoma of skin of left upper eyelid, including canthus.
    1–10 of 71
    1/8
    Dose interval
    Dose interval — cutaneous squamous cell carcinoma (cSCC)Every 42 days (cSCC dosing interval)
    Dose interval — all other indicationsEvery 21 days (all other indications dosing interval)
    Reference unitIntervals correspond to 700 mg every 42 days for cSCC and 350 mg every 21 days for other indications (see quantity limits)
    Tumor Mutational Burden
    Example TMB threshold> 50 mutations/megabase (example threshold cited for ultra-hypermutated phenotype)
    Context of use

    Prior Authorization, Documentation and Operational Notes

    Prior Authorization

    Prior authorization validity

    Prior authorization is required. Initial authorizations are provided for 180 days (6 months) and may be renewed every 180 days thereafter unless an indication-specific limit applies (see neoadjuvant, adjuvant, and indication-specific maximums).

    Prior Authorization

    Renewal requirements

    Renewals are allowed only when the member continues to meet universal and indication-specific criteria, the original authorization duration has not been exceeded, there is no unacceptable toxicity, and disease response or stabilization is demonstrated.

    • Member continues to meet universal and indication-specific criteria (including concomitant therapy requirements and performance status)
    • Duration of authorization has not been exceeded (refer to Section I)
    • Absence of unacceptable toxicity
    • Disease response defined as stabilization or decrease in tumor burden

    Background, Definitions and Test Requirements

    Background: Cemiplimab (Libtayo) is an intravenous anti–PD‑1 monoclonal antibody indicated across multiple advanced or metastatic malignancies and select biomarker‑defined tumors. The policy covers FDA‑approved and compendia‑recommended uses including cutaneous squamous cell carcinoma (cSCC) (metastatic, locally advanced, recurrent, adjuvant, and neoadjuvant in defined situations), basal cell carcinoma (BCC), non‑small cell lung cancer (NSCLC) with biomarker and PD‑L1 guided branches, and single‑agent use for MSI‑H/dMMR or POLE/POLD1 ultra‑hypermutated tumors (for example in small bowel, colon, appendix, and rectal cancers). Dosing is typically 350 mg IV every 3 weeks for most indications with indication‑specific exceptions (e.g., 700 mg every 6 weeks as part of an adjuvant option for cSCC); prior authorization is required and initial authorization is issued for 180 days with renewal rules and maximum duration limits specified by indication.

    Actionable biomarkers
    Actionable biomarkers listEGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, NRG1, and ERBB2 (HER2)
    Testing expectationsComplete molecular testing (including the listed biomarkers) via biopsy and/or plasma testing is expected prior to selecting therapy
    Impact on treatmentIf a clinically actionable marker is found, treatment may be guided by that marker; unknown results are treated as absence of driver oncogenes

    Step Therapy and Prior Treatment Positioning

    Indication / ContextStep Therapy Positioning
    Non-Small Cell Lung Cancer (NSCLC)Cemiplimab may be used in combination with platinum-based chemotherapy as first-line therapy for: (a) tumors negative for actionable biomarkers, or (b) tumors positive for select biomarkers (EGFR exon 20 insertion, BRAF V600E, NTRK fusions, MET exon 14 skipping, NRG1 fusion, ERBB2). Also used in combination with pemetrexed as continuation maintenance after response to first-line cemiplimab-containing regimens. No explicit prerequisite prior-line therapy required for these first-line combination branches in this section.
    SummaryPolicy Action / Note
    Multi-step prior therapy requirementNo explicit multi-step prior therapy is specified in the shown appendices. Prior authorization is applied/considered based on utilization management and NQTL assessment, with cost flagged as a factor for PA consideration.
    ScopeInstruction
    Step therapy requirements in appendicesThese appendices do not specify step therapy edits; refer to the main policy clinical criteria sections for any step therapy requirements or edits relevant to coverage decisions.

    Dose Limits and Maximum Therapy Duration

    cemiplimab-rwlc dosing
    Dose per administration — cSCC700 mg per dose for cSCC (maximum units per dose) — corresponds with 700 billable units
    Dose per administration — other indications350 mg per dose for all other indications
    Billing noteDosing schedules reference 350 mg IV q3w for many indications and 700 mg every 6 weeks as an alternative adjuvant cSCC schedule (see dosage/administration)
    Quantity limits (doses over time)
    Maximum doses over time (cSCC/BCC metastatic or locally advanced)35 doses over 24 months for metastatic/locally advanced cSCC and BCC
    ContextRenewal for these indications may be provided up to the 24‑month/35‑dose limit in members without progression or unacceptable toxicity

    Administration Setting and Billing Considerations

    Note

    Intravenous administration

    Libtayo is administered intravenously as listed in the policy.

    Billing Rule

    Infusion billing and site of care

    Bill cemiplimab by HCPCS J9119 (Injection, cemiplimab‑rwlc, 1 mg) and provide infusion administration in an infusion center, hospital outpatient, or office infusion setting per standard oncology practice.

    • J9119 — Injection, cemiplimab‑rwlc, 1 mg; 1 billable unit = 1 mg
    • Typically provided in infusion centers or hospital outpatient/office infusion settings
    Policy Summary
    PayerViva Health
    PolicyLibtayo (cemiplimab-rwlc) — coverage and prior authorization
    Policy CodePolicy IC-0398
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial approval valid for 180 days; renewable every 180 days when criteria are met).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaInitial Authorization and Dosing RequirementsRenewal, Continuation and Treatment LimitsBilling Codes, Diagnosis Codes and Dosing UnitsPrior Authorization, Documentation and Operational NotesBackground, Definitions and Test RequirementsStep Therapy and Prior Treatment PositioningDose Limits and Maximum Therapy DurationAdministration Setting and Billing Considerations
    Continuation maintenance: Used as continuation maintenance therapy in members who achieved tumor response or stable disease after first-line cemiplimab-containing regimens (including cemiplimab + pemetrexed for non-squamous histology)

    Applies to continuation maintenance following response/stability on first-line cemiplimab-containing regimens.

    Administer 350 mg IV every 3 weeks for 12 weeks then 700 mg every 6 weeks OR 350 mg every 3 weeks up to a maximum of 48 weeks
    max 48 weeks
    Neoadjuvant cSCC: Administer 350 mg IV every 3 weeks for up to 4 dosesmax 4 doses

    Prior authorization for neoadjuvant cSCC may not be renewed (limited to initial authorization period).

    Cervical/Vaginal/Vulvar Cancer: Administer 350 mg IV every 3 weeks up to a maximum of 96 weeks in members without progression or unacceptable toxicitymax 96 weeks
    Basal Cell Carcinoma (BCC): Administer 350 mg IV every 3 weeks up to a maximum of 24 months in members without progression or unacceptable toxicitymax 24 months
    NSCLC/Small Bowel/Colon/Rectal/Anal Cancer: Administer 350 mg IV every 3 weeks until disease progression or unacceptable toxicity; for anal carcinoma combination therapy may be given up to 12 months (combo chemo up to 24 weeks then single-agent maintenance)

    Initial authorization — diagnosis requirement

    Initial authorization should be supported by a covered diagnosis code from Appendix 1.

    Diagnosis requirement: Presence of a covered ICD-10 diagnosis code from Appendix 1 accompanying the request

    Additional clinical criteria are located elsewhere in the full policy.

    Anal carcinoma renewal limit: Anal carcinoma in combination with paclitaxel and carboplatin, then continued as single agent: renewable up to a maximum of 12 months of therapy (17 total doses)17 doses / 12 months

    Renewal / Continuation Therapy

    Renewal/continuation rules

    Continuation criteria: Member continues to meet universal and indication-specific criteria (including concomitant therapy requirements and performance status), duration has not been exceeded, absence of unacceptable toxicity, and disease response or stabilization

    Members relapsing ≥ 6 months after discontinuation due to duration are eligible to re-initiate PD-directed therapy; cases with changed actionable mutations on re-biopsy evaluated case-by-case.

    Used to support POLE/POLD1 mutation‑driven indications and MSI-H/dMMR-related coverage in select GI tumors
    Test confirmationTMB determination should be by an FDA‑approved or CLIA‑compliant test as specified in the policy
    Medicare Part B Covered Diagnosis Codes
    Medicare Part B covered diagnosis codes (document)N/A in this document section — follow applicable NCDs/LCDs where present
    GuidanceRefer to CMS Medicare Benefit Policy Manual, NCDs, LCDs, and LCAs for Part B coding and coverage determinations
    Search resourceCMS coverage database: https://www.cms.gov/medicare-coverage-database/search.aspx
    Documentation Required

    Diagnosis code required

    Submit one of the ICD-10 diagnosis codes listed in Appendix 1 with the request to document an indicated malignancy.

    Note

    NSCLC regimen positioning

    For first-line NSCLC when used in combination with platinum-based chemotherapy, cemiplimab is applied per the regimen described (combination or continuation maintenance branches); no explicit prerequisite therapies are specified in this section for these first-line combination regimens.

    • Used in combination with platinum-based chemotherapy as first-line therapy for tumors negative for actionable biomarkers or for select biomarker-positive tumors
    • Continuation maintenance allowed after response to first-line cemiplimab-containing regimens
    Note

    PA consideration per NQTL

    Prior authorization is applied following the Non‑Quantitative Treatment Limitations (NQTL) assessment; cost was identified as a factor considered for PA in the NQTL checklist.

    • NQTL checklist notes cost of drug as a factor for consideration of prior authorization
    • Utilization management/PA is applied comparably across benefit types per the NQTL assessment
    Step Therapy

    Step therapy not specified here

    No step therapy (multi‑step prior‑therapy) requirements are specified in the provided sections; refer to other sections of the policy for any clinical step edits.

    • The extract does not list prerequisite failure steps for Libtayo
    • Check the main policy content for any step therapy edits not shown here
    Documentation Required

    Biomarker testing documentation

    For NSCLC and other biomarker‑directed indications, documentation of biomarker testing (actionable biomarkers and PD‑L1 TPS) from an FDA‑approved or CLIA‑compliant test is expected to determine appropriate use.

    • PD‑L1 Tumor Proportion Score (TPS) when applicable must be determined by an FDA‑approved or CLIA‑compliant test
    • Actionable biomarker testing (per policy-listed biomarkers) via FDA‑approved or CLIA‑compliant assays
    Documentation Required

    Required clinical documentation

    Clinical documentation must show single‑agent use when required, biomarker status (e.g., MSI‑H/dMMR or POLE/POLD1 with ultra‑hypermutated/TMB evidence determined by FDA‑approved or CLIA‑compliant testing), disease extent (recurrent, progressive, metastatic or locally unresectable), and prior treatments where relevant.

    • Evidence of single‑agent use when the indication requires single‑agent therapy
    • Biomarker status documented by FDA‑approved or CLIA‑compliant test (MSI‑H/dMMR or POLE/POLD1 with example TMB > 50 mut/Mb)
    • Disease extent (advanced/metastatic, locally unresectable, recurrent/progressive) and relevant prior therapies
    • Documentation of response or stability for renewals
    Documentation Required

    Submit covered diagnosis code

    When submitting a request, include the applicable ICD‑10 diagnosis code from Appendix 1 that supports medical necessity for Libtayo.

    Denial Risk

    Prior PD‑1/PD‑L1 therapy restriction

    Prior authorization may be denied if the member has received previous PD‑1/PD‑L1‑directed therapy unless the policy or indication explicitly allows prior PD‑1/PD‑L1 therapy.

    • Universal criteria state member has not received previous PD‑1/PD‑L1 therapy unless otherwise specified
    Denial Risk

    Renewal denial triggers

    Renewal may be denied if the authorization duration has been exceeded, unacceptable toxicity is present, or disease response/stabilization is not demonstrated.

    • Duration limits per indication (see Section I) must not be exceeded
    • Presence of unacceptable toxicity (examples listed in policy) will preclude renewal
    • Lack of disease response or stabilization may result in denial
    Billing Rule

    Medicare policy compliance

    Comply with applicable Medicare coverage determinations (NCDs/LCDs/LCA) for Part B outpatient drugs where relevant; noncompliance with Medicare rules may affect coverage.

    • Medicare coverage guidance in the Medicare Benefit Policy Manual and any applicable NCDs/LCDs must be followed
    • Medicare Part B covered diagnosis codes are listed as N/A in this extract—check applicable NCD/LCD
    Ultra-hypermutated phenotype
    Ultra-hypermutated phenotype exampleTumor mutational burden > 50 mutations/megabase (example) used to support POLE/POLD1 mutation-driven indications
    Clinical applicationUsed as part of biomarker requirement for appendiceal and rectal (and other specified) tumor coverage when POLE/POLD1 mutation is present
    Confirmation requirementTMB and POLE/POLD1 status should be determined by an FDA‑approved or CLIA‑compliant test
    FDA-approved or CLIA-compliant test
    Accepted assaysLaboratory assays recognized by the FDA or certified under CLIA for determining MSI-H/dMMR, POLE/POLD1 mutation, and TMB
    PurposeUsed to confirm biomarker eligibility for MSI-H/dMMR or POLE/POLD1 ultra-hypermutated indications in the policy
    Example noteIf confirmed using an FDA approved assay, reference provided to FDA companion diagnostics guidance
    ICD-10 codes in Appendix 1
    ICD-10 Appendix 1Appendix 1 lists covered ICD-10 diagnosis codes that support medical necessity for Libtayo (see Appendix 1 code list)
    Provider actionSubmit the applicable ICD-10 diagnosis code from Appendix 1 with authorization requests to demonstrate indicated malignancy
    Example codes includedAppendix entries include codes such as C34.82, C34.90–C34.92, C44.01–C44.02, and many others (see full appendix)
    CMS national or local coverage determinations
    Medicare NCD/LCD/LCA relevanceNational and local coverage determinations and related articles may exist and must be followed where applicable
    Where to checkUse the CMS Medicare Coverage Database to locate applicable NCDs, LCDs, or LCAs
    Effect on Part BMedicare-specific rules may affect outpatient/Part B administration and claims payment for Libtayo; compliance is required
    Related limitsOther indications have different renewal maxima (e.g., adjuvant cSCC up to 48 weeks; cervical/vaginal/vulvar up to 96 weeks)
    Billing and vial information
    Billing format for LibtayoPer dosing schedule; 350 mg vials billed by mg via HCPCS J9119 (Injection, cemiplimab‑rwlc, 1 mg)
    Unit definitionJ9119 is billed per 1 mg unit (1 billable unit = 1 mg)
    Administration settingTypically administered intravenously in infusion centers or outpatient/office infusion settings with J9119 billing
    Billing Rule

    Medicare outpatient/Part B administration rules

    Medicare-specific rules may apply for outpatient/Part B administration—refer to CMS manuals and any applicable NCDs/LCDs when billing Medicare.

    • Consult the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 and search the CMS coverage database for applicable NCDs/LCDs/LCAs